. >>> one of the great growth stories all the time crl, once again ready to roar?es river provides universities and biopharmaceutical firms with everything they need to discover new drugs, conduct trials, club the lab rats and mice that any potential drug needs to be tested on. companies tools makes the whole process both faster and more efficient, and of course cheaper, which is why biotech and pharma companies are increasely outsourcing the work to charles river and others like it. rallied last year. we had faith it was on fire. then from the first week of april through the first week of may it dropped from 61 down to 50 and spent the next three months stuck in the low 50s, in part because of worries that drug companies were shifting resource budgets away from the early stage toward firms that specialize in later-stain trials. . crl off an 812 basis with higher than expected revenues. they did make an acquisition there. management raised the full-year guidance, so this stock with a 50% gain 20 months allege ready to resume the long march higher? let's take a look